GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Net Income From Continuing Operations

Transgene (XPAR:TNG) Net Income From Continuing Operations : €-22.33 Mil (TTM As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Transgene Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Transgene's net income from continuing operations for the six months ended in Dec. 2023 was €-6.43 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €-22.33 Mil.

Transgene Net Income From Continuing Operations Historical Data

The historical data trend for Transgene's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Net Income From Continuing Operations Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.80 -17.23 -19.54 -32.80 -22.33

Transgene Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.74 -15.28 -17.53 -15.90 -6.43

Transgene Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-22.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene (XPAR:TNG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Net Income From Continuing Operations
Comparable Companies
XPAR:ADOC XPAR:DBV XPAR:MAAT XPAR:IVA XPAR:AELIS XPAR:OSE XPAR:ALVAL XPAR:GNFT XPAR:GNRO XPAR:IPH OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TGNA:Germany
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400
Website
https://www.transgene.fr
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.

Transgene (XPAR:TNG) Headlines

No Headlines